Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Samsung Biologics to develop Aprinoia's Alzheimer’s treatment
By Lim Jeong-yeoPublished : March 17, 2020 - 14:48
Samsung Biologics said Tuesday it has signed a deal to develop Taiwanese bio firm Aprinoia’s Alzheimer’s disease treatment.
Aprinoia Therapeutics is a bioventure with specialized technology in diagnostic devices and treatments for neurodegenerative diseases.
It is a leader and pioneer in the development of monoclonal antibodies against the tau protein, known to be the key trigger of Alzheimer’s.
The tau protein is what binds and stabilizes the internal structures within brain cells, or neurons. In the case of Alzheimer’s patients, however, these tau proteins stick to each other instead, disrupting the normal brain system.
Through this contract development deal, Samsung Biologics will manufacture clinical sample of Aprinoia’s Alzheimer’s treatment pipeline and help its application for clinical tests as an investigational new drug.
This CDO deal will help Samsung Biologics effectively expand its business to cover the greater China. It is already negotiating with some 20 Chinese companies.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
Aprinoia Therapeutics is a bioventure with specialized technology in diagnostic devices and treatments for neurodegenerative diseases.
It is a leader and pioneer in the development of monoclonal antibodies against the tau protein, known to be the key trigger of Alzheimer’s.
The tau protein is what binds and stabilizes the internal structures within brain cells, or neurons. In the case of Alzheimer’s patients, however, these tau proteins stick to each other instead, disrupting the normal brain system.
Through this contract development deal, Samsung Biologics will manufacture clinical sample of Aprinoia’s Alzheimer’s treatment pipeline and help its application for clinical tests as an investigational new drug.
This CDO deal will help Samsung Biologics effectively expand its business to cover the greater China. It is already negotiating with some 20 Chinese companies.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
